Cerebral Palsy
Neurocrine NBI-98854-DCP3018
This study is designed to evaluate the safety, efficacy, and tolerability of Valbenazine for the
treatment of dyskinesia due to cerebral palsy. Valbenazine works by slowing down the
release of dopamine in the brain, thus reducing the uncontrolled, jerky movements known
as dyskinesia. The first phase (14 weeks) of the study involves the participant either
receiving Valbenazine or placebo. The first phase is followed by a two-week washout period
(no treatment) and then a 32-week open-label treatment phase where the participant
received definite medication.
Learn more: https://classic.clinicaltrials.gov/ct2/show/NCT05206513
Essential Tremor
AbbVie M21-471
This study is designed to evaluate the efficacy and safety of BOTOX (Botulinum Toxin Type
A) in individuals (18 to 80 years of age) who experience upper arm essential tremor (ET).
BOTOX works to block neuromuscular transmission by binding to accepter sites on nerve
terminals, essentially reducing the frequency and force of movement in essential tremor.
The injectable therapy would be administered in 12-week cycles with a total of three
injection visits for up to 36 weeks. The first two injections would be in the dominant arm,
and the last one would be in both arms. Being that the clinical trial is placebo-controlled,
the participant will either receive the placebo or BOTOX for all three injection periods. The
aim of this study is to expand the treatment options for upper arm ET to avoid the use of
high-risk non-pharmacological/surgical interventions.
Learn more: https://clinicaltrials.gov/study/NCT05216250?tab=history&a=18